CA2944262C - Improved stem cell composition - Google Patents

Improved stem cell composition Download PDF

Info

Publication number
CA2944262C
CA2944262C CA2944262A CA2944262A CA2944262C CA 2944262 C CA2944262 C CA 2944262C CA 2944262 A CA2944262 A CA 2944262A CA 2944262 A CA2944262 A CA 2944262A CA 2944262 C CA2944262 C CA 2944262C
Authority
CA
Canada
Prior art keywords
cells
cell culture
angl
population
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944262A
Other languages
English (en)
French (fr)
Other versions
CA2944262A1 (en
Inventor
Silviu Itescu
Paul Simmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901247A external-priority patent/AU2014901247A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CA2944262A1 publication Critical patent/CA2944262A1/en
Application granted granted Critical
Publication of CA2944262C publication Critical patent/CA2944262C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2944262A 2014-04-07 2015-04-07 Improved stem cell composition Active CA2944262C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901247A AU2014901247A0 (en) 2014-04-07 Improved stem cell composition
AU2014901247 2014-04-07
PCT/EP2015/057521 WO2015155187A1 (en) 2014-04-07 2015-04-07 Improved stem cell composition

Publications (2)

Publication Number Publication Date
CA2944262A1 CA2944262A1 (en) 2015-10-15
CA2944262C true CA2944262C (en) 2023-08-01

Family

ID=53724311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944262A Active CA2944262C (en) 2014-04-07 2015-04-07 Improved stem cell composition

Country Status (9)

Country Link
US (4) US10400218B2 (cg-RX-API-DMAC10.html)
EP (2) EP3129468B1 (cg-RX-API-DMAC10.html)
JP (4) JP6882161B2 (cg-RX-API-DMAC10.html)
KR (2) KR102577698B1 (cg-RX-API-DMAC10.html)
CN (2) CN113337462A (cg-RX-API-DMAC10.html)
AU (4) AU2015243575B2 (cg-RX-API-DMAC10.html)
CA (1) CA2944262C (cg-RX-API-DMAC10.html)
SG (2) SG10202000644TA (cg-RX-API-DMAC10.html)
WO (1) WO2015155187A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
KR102577698B1 (ko) 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
JP6231709B1 (ja) * 2016-05-31 2017-11-15 シスメックス株式会社 蛍光画像分析装置および分析方法
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
WO2022173737A1 (en) 2021-02-09 2022-08-18 Millennium Pharmaceuticals, Inc. Methods and compositions for freezing and thawing mammalian cells
JP2025538783A (ja) * 2022-12-09 2025-11-28 メゾブラスト・インターナショナル・エスアーエールエル 事前承認された組成物及び細胞培養方法
AU2023389700A1 (en) * 2022-12-09 2025-07-10 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
WO2024121821A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
JP2003052360A (ja) * 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
KR20050111593A (ko) * 2003-02-19 2005-11-25 가부시키가이샤 디나벡크 겐큐쇼 허혈질환의 치료방법
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790B (zh) * 2008-10-30 2010-09-29 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
EP2258413A1 (en) * 2009-06-04 2010-12-08 Université Catholique de Louvain Multi-dimensional biomaterial and method for producing the same.
JP5888670B2 (ja) * 2010-11-18 2016-03-22 国立大学法人東京工業大学 骨芽細胞分化誘導用培養基材、骨芽細胞分化誘導方法、及び骨芽細胞製造方法
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
KR102019540B1 (ko) * 2013-12-18 2019-09-06 아이디에이씨 홀딩스, 인크. 전이중 무선 시스템에서의 간섭 관리 방법, 장치 및 시스템
KR102577698B1 (ko) * 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물

Also Published As

Publication number Publication date
AU2022200640A1 (en) 2022-02-24
US20250136944A1 (en) 2025-05-01
JP7571109B2 (ja) 2024-10-22
US20190345452A1 (en) 2019-11-14
KR20160145066A (ko) 2016-12-19
AU2018200619B9 (en) 2020-05-07
JP2024177516A (ja) 2024-12-19
JP7196216B2 (ja) 2022-12-26
AU2018200619B2 (en) 2020-01-02
US20230030428A1 (en) 2023-02-02
CN106459913B (zh) 2021-05-18
KR20220080023A (ko) 2022-06-14
KR102405663B1 (ko) 2022-06-07
US10400218B2 (en) 2019-09-03
KR102577698B1 (ko) 2023-09-12
WO2015155187A1 (en) 2015-10-15
AU2024203197A1 (en) 2024-05-30
EP3129468A1 (en) 2017-02-15
CA2944262A1 (en) 2015-10-15
US20170107495A1 (en) 2017-04-20
AU2022200640B2 (en) 2024-02-15
CN106459913A (zh) 2017-02-22
AU2015243575B2 (en) 2017-11-02
SG10202000644TA (en) 2020-03-30
EP3129468B1 (en) 2022-09-21
SG11201607925SA (en) 2016-10-28
EP4137560A1 (en) 2023-02-22
JP2017512842A (ja) 2017-05-25
AU2020202214B2 (en) 2021-11-18
AU2018200619A1 (en) 2018-02-15
AU2020202214A1 (en) 2020-04-16
US11312941B2 (en) 2022-04-26
JP2021080272A (ja) 2021-05-27
AU2015243575A1 (en) 2016-10-13
CN113337462A (zh) 2021-09-03
JP2023021279A (ja) 2023-02-10
JP6882161B2 (ja) 2021-06-02

Similar Documents

Publication Publication Date Title
AU2022200640B2 (en) Improved stem cell composition
JP7279212B2 (ja) 免疫疾患の治療
US20250325591A1 (en) Therapy for hepatic disorders using adipose-derived mesenchymal stem cell line
HK40088316A (en) Improved stem cell composition
HK1227933B (en) Improved stem cell composition
HK1227933A1 (en) Improved stem cell composition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200331

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250318

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317